Welcome to our dedicated page for RIDGETECH news (Ticker: RDGT), a resource for investors and traders seeking the latest updates and insights on RIDGETECH stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RIDGETECH's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RIDGETECH's position in the market.
Ridgetech (NASDAQ:RDGT) reported its fiscal year 2025 results, marked by strategic transformation. Revenue reached $119.97 million, a slight decrease of 3.2% from the previous year. The company reported net income of $10.20 million ($1.84 per share), compared to a net loss of $4.23 million in FY2024.
Key developments include the divestiture of retail pharmacy operations and the acquisition of Ridgeline and Allright, marking expansion into online wholesale distribution. The newly acquired online platform contributed 1% of total revenue with a 7.4% gross margin. Overall gross margin decreased to 3.2% from 3.9% year-over-year, while sales and marketing expenses increased by 64.2%.
The company's cash position strengthened to $12.78 million as of March 31, 2025, up from $2.30 million the previous year, with operating activities providing $1.25 million in cash flow.